W E ARE assembled here at this time to express our respect and esteem for Dr. Lewis Atterbury Conner through this lectureship established in his honor. In reality, all the activities of the American Heart Association are a lasting tribute to him. For he was one of its founders, the creator and first editor of the American Heart Journal. Particularly at this moment, six months after his death on December 4, 1930 , it is gratifying to know, that regardless of the time and the place of our meetings, and regardless of the changing program committees, 1)r. Lewis A. Conner will always, through this lectureship, participate in the scientific proceedings of our association.
But long before his 83 years had ended, he had become an unforgettable legend. For his was a vibrant and compelling personality. Poise, reserve, dignity, and an almost austere rectitude characterized the immediate impact on meeting him. Sympathy, warmth and wisPresetited at the scientific session of the Twenttfourth Annual Meeting of the American Heart Association, Atlantic City, N. J., June 9, 1951. From the Department of Medicine, Harvard Universitv Medical School, Boston His place in the history of medicine is assured by genuine scientific achievement based on bedside experience. His numerous publications cover practically every aspect of the cardiovascular system and repeated reference is made to the effects of the thyroid. The subject of the lecture today, "The Heart and the Thyroid; with Particular Reference to I111 Treatment of Chronic Heart Disease" seems, therefore, appropriate.
The interrelationship of the thyroid and the heart has enjoyed a long and honorable tradition. Parry's original description of exophthalmic goiter in 1786, published in 1825,1 is recorded, indeed, as a form of heart disease at the beginning of the chapter entitled "Diseases of the Heart." Parry thereupon describes the clinical manifestations of exophthalmic goiter and their association with congestive failure and angina pectoris in these patients. With the exacerbation of the signs and symptoms of toxic goiter, evidences of congestive failure and/or angina pectoris became more severe.
He also notes the parallel subsidence of both groups of manifestations. With of the characteristic features are absent but in which the manifestations of coexistent heart disease are markedly ameliorated or even abolished after appropriate treatment of the thyrotoxicosis.' Interest in the subject in this country may be gaged by the fact that the 1932 meeting of the American Heart Association was devoted entirely to a symposium on "The Thyroid Heart."
The effect of the hyperactive thyroid on the cardiovascular system has been studied extensively. Important insight has been gained into the meaning of the signs and symptoms of hyperthyroidism that are commonly attributed to heart disease. Velocity of Blood Flow That the speed of blood flow is increased greatly in thyrotoxicosis was shown in 1927 and 1928. 5 We injected the radioactive deposit of radium emanation, that is, radium C, and, by means of Geiger Counters, measured the pulmonary circulation time. The proportionality between the speed of blood flow and the basal metabolic rate is shown in figure 1. Minute Volume Output of the Heart
The patient with hyperthyroidism has a greatly increased cardiac output. Recent studies employing the direct Fick principle by means of catheterization show that with increases in the metabolic rate averaging 35 per cent above normal, cardiac output increases 45 per cent above normal.6 Under such circumstances the cardiac output in thyrotoxic patients at rest corresponds to that of normal individuals doing light work. This increase in minute volume output is accomplished by increasing the number of heart beats, at times by an increase in the output of blood per beat or by a combination of both. The work of the heart is increased not only at rest but even more on effort. Plummer and Boothby,7 many years ago, observed that a given amount of effort produces a disproportionate rise in output in patients with hyperthyroidism as compared with normal subjects; the "cost of work" is great.
The increased output of the heart in hyperthyroidism evidently serves two main purposes. More blood is supplied to sustain the increased oxygen consumption of the tissues of the body. Also, the body temperature is held constant by a greatly increased blood flow through the skin, with dissipation of the increased heat generated within the body. The internal environment of the body is maintained thereby at a normal temperature. It recently has been shown by Stead and his associates, indeed, that the increased output of the heart in hyperthyroidism is distributed mainly to the skin, muscles and kidneys; the brain and splanchnic area receiving little or no increased blood supply.6' 8, The blood and extracellular fluid volume is also increased; the increased pulmonary blood volume leads to a diminished vital capacity and dyspnea.'0
The cardiovascular manifestations of hyperthyroidism are not to be considered merely as an expression of hypermetabolism. In regard to the tachycardia of hyperthyroid animals, it has been shown that this will persist after the heart has been isolated from the peripheral vascular tree and from all neural pathways. Markowitz and Yater, moreover, showed that thyroxin causes "tachycardia" to occur in fragments of heart muscle removed from two-day chick embryos before any nerve cells within the heart or neural pathways to the heart have been formed.'3 Although the available data are not conclusive as to the precise mechanism by which thyroid hormone affects cellular metabolism, some of the critical enzyme systems are evidently implicated."4 15 The Opinions differ as to whether angina pectoris or congestive heart failure ever occur in thyrotoxicosis without coexistent heart disease.
Clinically, however, there can be no question but that alleviation of the hyperthyroidism in many instances is accompanied by marked amelioration or even complete disappearance of the angina pectoris and congestive heart failure. Such patients may have a degree of coronary arteriosclerosis or other organic lesions which, by themselves, are insufficient to cause clinical manifestations in the absence of the additional strain imposed by hyperthyroidism. The degree of relief of congestive failure and angina pectoris is so remarkable that "thyroid heart disease" is often classified as one of the "curable" forms of cardiovascular disorders. Congestive failure frequently masks the clinical hallmarks of hyperthyroidism. Particularly in the older age groups, all eye signs, tremor and nervousness may be absent, the thyroid normal its size. The vigorous and roughened first heart sound with apical presystolic murmur and thrill, the systolic murmur, cardiac enlargement, or auricular fibrillation and rapid rate in the presence of congestive failure may lead to an erroneous diagnosis of mitral valvular disease.
The diagnosis frequently will be missed and the crippled cardiac patient will be deprived of his only opportunity of recovery unless we suspect the presence of thyrotoxicosis in one of its manifold manifestations in every cardiac patient and assure ourselves of its presence or absence.
We In the appraisal of therapy of angina pectoris and congestive failure, it is necessary to bear in mind that the clinical course is often irregular and characterized by periods of unexpected remission and improvement. We, therefore, have selected only patients who, despite marked restriction of activities for many months or years, showed evidence of continued incapacity after having received all standard forms of therapy and in whom remissions of the disease were absent or who continued to suffer signs and symptoms even during periods of slight remission. In all patients included in this report, reliable information regarding the characteristics and severity of the clinical course was available. Some patients had been observed for years in the cardiac clinic of the Beth Israel Hospital and on the wards; others were referred by physicians who placed their records at our disposal. Each patient was appraised independently by several of us before a decision was reached; in many instances, our appraisal was based on observation and study of the patient, including exercise tolerance" and other tests, over a period of many weeks or months before radioactive iodine therapy was instituted. Following the administration of J131, the period of 6 to 26 weeks before the development of definite hypothyroidism served as an additional control period.
RESULTS IN In the 26 patients with angina pectoris rendered hypothyroid by J'31, the therapeutic result has been decidedly worthwhile in 19. In each instance, the patient has been able to undertake activities which had been impossible for many months or years prior to treatment. occurred eight months before treatment. He had been unable to work during the nine months before treatment and had been restricted largely to the house because walking even a hundred feet precipitated an attack. He was awakened from sleep by anginal attacks, often suffering three or four episodes nightly. He noted increasing dyspnea and used two pillows. In the month prior to J131 therapy, he had used over 500 tablets of nitroglycerine. During his illness, he had received the following treatment; theobromine sodium acetate, potassium iodide, sedatives, quinidine, atropine; nitroglycerine alone was of slight help. There was no history of arterial hypertension or of rheumatic or syphilitic infection.
Physical examination revealed entirely normal findings. The blood pressure was 110/80. The urine and blood were normal. On x-ray examination, the heart was normal in size and shape. The electrocardiogram showed changes consistent with an old posterior infarct.
Post Although it is too early to formulate final 2"31 TREATMENT OF HEART DISEASE indications and contraindications, it is nevertheless desirable to offer a tentative opinion regarding the criteria for the proper selection based on our experience in these 39 patients observed after treatment, on the average, for 23 months. Unfavorable factors which incline us to advise against treatment may be summarized as follows:
1. Rapidly progressive cardiovascular disease (malignant hypertension, syphilitic cardiovascular disease). There is no reason to believe that hypothyroidism retards the progression of the underlying pathologic process. Even though the patient may experience improvement for a few weeks or months after treatment, a relapse to his former clinical condition is likely to occur if a rapidly advancing pathologic process underlies his difficulties. It is also unwise to treat patients who are in the terminal phases of their disease, particularly since five weeks to six months intervene before the hypometabolic state is attained. However, the presence of moderate or even marked hypertension does not contraindicate the treatment. 3. Associated conditions. The presence of other conditions which may incapacitate the patient and becloud evaluation of this method of treatment constitutes a contraindication. These include active infection such as rheumatic fever, bronchiectasis, emotional instability, cirrhosis of the liver and recent acute myocardial infarction. Intermittent claudication is not benefited by the induction of hypometabolism; on the contrary it may be aggravated and constitutes a definitely unfavorable factor. Similarly, the symptoms of severe painful hypertrophic arthritis may be aggravated.
Favorable Factors. Patients who may be expected to gain the greatest benefit are those in whom the disease has been relatively stationary or only slightly progressive over a period of one or more years. Even though such patients may be seriously incapacitated and may have angina pectoris at rest in bed, if their condition has been quite stable over a period of three months or more, a favorable response to this treatment is likely. Patients with congestive failure should show evidence of some cardiac reserve, such as ability to lose the signs of congestive failure on rest in bed or with the use of diuretics and digitalis. The basal metabolic rate should be above -15 per cent. It is also important that the patient be alert, cooperative and emotionally stable. When patients are frankly myxedematous with basal metabolic rates of -30 to -40 per cent they are often irritable and nervous. On receiving small doses of thyroid to maintain them at a level of -15 to -25 per cent, they are frequently more stable emotionally than before treatment, and mentally as acute as formerly. In an occasional patient, such as J. K., this factor may be significant; the patient stating that all his life prior to treatment he was prone "to fly off the handle whereas now I am more even-tempered." The precise mechanisms responsible for these effects are not clear though the adrenal and other endocrine organs may well be involved. Repeated administration of J131 is particularly indicated when thyroid adenomata are present. In some patients, these adenomata are plainly evident at the time of initial examination. In others they have become apparent only after the normal thyroid has disappeared following the first one or two doses of F"31. Presumably these nodules are initially nonfunctioning and do not take up J131 until the normal thyroid tissue has been destroyed. The adenomata apparently then begin to function and may be affected by subsequent doses of J131. Subsequent doses are frequently followed by tenderness of the nodule, its gradual disappearance, and the induction of myxedema with its characteristic clinical manifestations.
It has been our practice to permit marked hypothyroidism or, in some instances, even complete myxedema to develop to assure ourselves that all thyroid tissue has been affected and then to give 6 or 12 mg. of thyroid (1i0 to 210 grain) daily. In each patient, thyroid dosage has been adjusted to maintain the patient at the lowest metabolic level at which he experiences the maximum relief from his cardiac disease and the minimum discomfort from myxedema. In certain individuals this may not be possible, the patient showing little or no improvement over his pretreatment status when sufficient thyroid is administered to obviate the discomfort of myxedema. Most patients are maintained at a basal metabolic level of approximately -20 to -25 per cent on a daily dosage of 6 to 30 mg. thyroid.
Occasionally patients may suffer a recurrence of their symptoms due to the fact that residual thyroid tissue has regenerated with return of the metabolic rate to pretreatment levels. In such instances, thyroid is withdrawn and if tracer doses show uptake of F"31, an additional therapeutic dose is administered.
In addition to these special considerations, the same careful supervision and therapeutic program indicated inl all patients with heart disease is essential. The As in previous studies, particular attention has been devoted to the appearance of evidence of the signs or symptoms of the so-called "myxedema heart." An increased cardiac silhouette or area of percussion dullness, decreased voltage of the electrocardiogram and less forceful pulsations on fluoroscopy have been observed in some of our subjects. But "myxedema heart" in the sense of a condition aggravating or precipitating attacks of angina pectoris or congestive failure did not develop. On the contrary, with the appearance of such changes, striking clinical improvement has been witnessed. In some patients with congestive failure, the cardiac silhouette becomes smaller, the disappearance of the dilatation of the failing heart offsetting the effect of myxedema on the heart. Our experience is consequently in accordance with that of Willius and Haines, 44 Means, White and Krantz45 and Christian,46 who concluded that "myxedema heart" in the sense of causing heart failure occurs rarely, if at all.
Results of Others
The experience of others in the treatment of intractable heart disease is confirmatory of our own results. Wolferth 3. Only patients were treated who were seriously incapacitated despite all conventional forms of therapy for many months or years.
4. Persistent hypothyroidism can be regularly induced by one or more appropriate doses of radioactive iodine.
5. No radiation sickness and no toxic effects on the blood, kidneys or parathyroids have been observed. Mild or moderate transitory thyroiditis occurred in approximately one-half of the patients.
6. Twenty-six patients with severe angina pectoris have been treated. The average duration of angina pectoris before treatment was 5.6 years. The average follow-up period after treatment is two years and varies from one year to three years. One third of the patients obtained excellent improvement; in another third the improvement, while less, was distinctly worth while. In the remaining one-third the results were not worth while.
7. Among 13 patients severely ill with congestive failure, approximately one-half have shown worth-while improvement; in four it has been striking. The duration of the worthwhile improvement has averaged 20 months with a range of 9 to 35 months.
8. The results of two confirmatory series of cases similarly treated elsewhere have been reviewed.
